Engineered NS1 for Sensitive, Specific Zika Virus Diagnosis from Patient Serology

Page view(s)
44
Checked on Sep 28, 2024
Engineered NS1 for Sensitive, Specific Zika Virus Diagnosis from Patient Serology
Title:
Engineered NS1 for Sensitive, Specific Zika Virus Diagnosis from Patient Serology
Journal Title:
Emerging Infectious Diseases
Publication Date:
27 April 2021
Citation:
Yap, T. L., Hong, S. Y., Soh, J. H., Ravichandraprabhu, L., Lim, V. W. X., Chan, H.-M., … Sun, W. (2021). Engineered NS1 for Sensitive, Specific Zika Virus Diagnosis from Patient Serology. Emerging Infectious Diseases, 27(5), 1427–1437. doi:10.3201/eid2705.190121
Abstract:
Dengue virus (DENV) and Zika virus (ZIKV) belong to the Flaviviridae family of viruses spread by Aedes aegypti mosquitoes in tropical and subtropical areas. Accurate diagnostic tests to differentiate the 2 infections are necessary for patient management and disease control. Using characterized ZIKV and DENV patient plasma in a blind manner, we validated an ELISA and a rapid immunochromatographic test for ZIKV detection. We engineered the ZIKV nonstructural protein 1 (NS1) for sensitive serologic detection with low cross reactivity against dengue and developed monoclonal antibodies specific for the ZIKV NS1 antigen. As expected, the serologic assays performed better with convalescent than acute plasma samples; the sensitivity ranged from 71% to 88%, depending on the performance of individual tests (IgM/IgG/NS1). Although serologic tests were generally less sensitive with acute samples, our ZIKV NS1 antibodies were able to complement the serologic tests to achieve greater sensitivity for detecting early infections.
License type:
Attribution 4.0 International (CC BY 4.0)
Funding Info:
This research / project is supported by the National Medical Research Council - Zika Response Research Fund
Grant Reference no. : NMRC/ZRRF/0001/2016
Description:
ISSN:
1080-6040
1080-6059